CO2024004812A2 - Método para producir células t - Google Patents

Método para producir células t

Info

Publication number
CO2024004812A2
CO2024004812A2 CONC2024/0004812A CO2024004812A CO2024004812A2 CO 2024004812 A2 CO2024004812 A2 CO 2024004812A2 CO 2024004812 A CO2024004812 A CO 2024004812A CO 2024004812 A2 CO2024004812 A2 CO 2024004812A2
Authority
CO
Colombia
Prior art keywords
cells
regulatory
disclosed
expression construct
produce
Prior art date
Application number
CONC2024/0004812A
Other languages
English (en)
Inventor
Shin Kaneko
Shoichi Iriguchi
Yoshiaki Kassai
Keiko Sekiya
Atsushi Matsuda
Takayuki Sato
Original Assignee
Takeda Pharmaceuticals Co
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Univ Kyoto filed Critical Takeda Pharmaceuticals Co
Publication of CO2024004812A2 publication Critical patent/CO2024004812A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Se divulga un método para producir células T reguladoras que comprende la siguiente etapa: (1) Diferenciar células que se pueden diferenciar en células T reguladoras, a las que se introduce un constructo de expresión, en células T reguladoras; el constructo de expresión comprende: (a) Secuencia no codificante conservada (CNS) 1, CNS2, y CNS3 del gen Foxp3; (b) Un promotor; y (c) Un ácido nucleico que codifica FOXP3. También se divulgan células T reguladoras obtenidas según el método, y una composición farmacéutica que comprende las células T reguladoras.
CONC2024/0004812A 2021-09-27 2024-04-17 Método para producir células t CO2024004812A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021157187 2021-09-27
PCT/JP2022/035626 WO2023048275A1 (ja) 2021-09-27 2022-09-26 Ｔ細胞の製造方法

Publications (1)

Publication Number Publication Date
CO2024004812A2 true CO2024004812A2 (es) 2024-05-20

Family

ID=85720842

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0004812A CO2024004812A2 (es) 2021-09-27 2024-04-17 Método para producir células t

Country Status (9)

Country Link
JP (1) JPWO2023048275A1 (es)
KR (1) KR20240067089A (es)
CN (1) CN118056007A (es)
AR (1) AR127141A1 (es)
AU (1) AU2022349176A1 (es)
CA (1) CA3234008A1 (es)
CO (1) CO2024004812A2 (es)
TW (1) TW202330910A (es)
WO (1) WO2023048275A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345878A (zh) * 2022-03-23 2023-12-01 國立大學法人京都大學 控制性ｔ細胞之製造方法
WO2024071010A1 (ja) * 2022-09-26 2024-04-04 国立大学法人京都大学 Ｔ細胞の製造方法
CN116640728B (zh) * 2023-07-24 2023-10-20 呈诺再生医学科技(北京)有限公司 RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011371A (es) 2004-04-10 2006-12-20 Henkel Kgaa Tubo para rizar el cabello.
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
CA2688539A1 (en) 2007-05-30 2008-12-11 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP2009237558A (ja) 2008-03-05 2009-10-15 Semiconductor Energy Lab Co Ltd 半導体装置の駆動方法
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2797598A4 (en) 2011-09-13 2015-08-12 Igor Roninson TREATMENT OF DISEASES OR DISORDERS BY INDUCED NFKB TRANSCRIPTIONAL ACTIVITY
AU2013214783B2 (en) 2012-02-02 2017-07-06 Senex Biotechnology Inc. CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
EP2888232A1 (en) 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
CA2889526C (en) 2012-10-08 2020-10-13 Merck Patent Gmbh 2-aminopyridine compounds
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
KR20150092279A (ko) 2012-12-10 2015-08-12 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014180943A1 (en) * 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
WO2014194201A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
AR097894A1 (es) 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
MY180383A (en) 2013-12-24 2020-11-28 Harvard College Cortistatin analogues and syntheses and uses thereof
US9926319B2 (en) 2014-03-27 2018-03-27 Merck Patent Gmbh Pyridyl piperidines
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9745325B2 (en) 2014-04-18 2017-08-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US20160016951A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
CN108463548B (zh) * 2015-10-30 2023-04-18 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
JP7059481B2 (ja) 2016-06-23 2022-04-26 国立大学法人京都大学 Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法
JP6987338B2 (ja) * 2016-08-05 2021-12-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS
CA3068286A1 (en) * 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
WO2019040655A1 (en) * 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
EP3781673A1 (en) * 2018-04-18 2021-02-24 Ucl Business Ltd Method for enhancing the suppressive properties of treg cells
WO2020032179A1 (ja) 2018-08-10 2020-02-13 国立大学法人京都大学 Ｃｄ３陽性細胞の製造方法
WO2020040198A1 (ja) * 2018-08-22 2020-02-27 国立大学法人大阪大学 制御性ｔ細胞の作製法
CA3160113A1 (en) 2019-11-08 2021-05-14 Sangamo Therapeutics, Inc. Generation of engineered regulatory t cells

Also Published As

Publication number Publication date
AR127141A1 (es) 2023-12-20
KR20240067089A (ko) 2024-05-16
WO2023048275A1 (ja) 2023-03-30
CA3234008A1 (en) 2023-03-30
TW202330910A (zh) 2023-08-01
JPWO2023048275A1 (es) 2023-03-30
AU2022349176A1 (en) 2024-04-11
CN118056007A (zh) 2024-05-17

Similar Documents

Publication Publication Date Title
CO2024004812A2 (es) Método para producir células t
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
BR112017022224A2 (pt) processos integrados para produzir, e processo para preparar uma composição
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
CO2022014527A2 (es) Método y fármaco para tratar el síndrome de hurler
AR102678A1 (es) Producción de ácidos grasos y derivados
MY187663A (en) Process for the epoxidation of propene
MX2022007571A (es) Metodo de produccion de promotor de crecimiento vegetal, promotor de crecimiento vegetal y metodo de promocion de crecimiento vegetal.
ATE404664T1 (de) Aldehyddehyrdrogenase-gen
MY184725A (en) Process for the purification of biomass hydrolysate
MX350421B (es) Producción de partículas tipo virus de la rabia en plantas.
MX2017002844A (es) Proceso mejorado de produccion de acido (met)acrilico.
MY198780A (en) Process for the biological production of methacrylic acid and derivatives thereof
SA519410599B1 (ar) تحسين التعبير عن بروتيازات سيرين في خلايا عائلة
MX2017011220A (es) Metodos para hacer celulas madre neurales y usos de las mismas.
AR116615A2 (es) Operaciones de cosecha mejoradas para proteínas recombinadas
MX2021001528A (es) Metodo para la produccion de celulas positivas para cd3.
MX2023002221A (es) Sistema de baculovirus modificado para produccion mejorada de adn de extremo cerrado (adnce).
BR112022011495A2 (pt) Usina e processo de produção de amônia e ácido sulfúrico integrados
BR112021024508A2 (pt) Métodos para desacoplar rendimento e produtividade de um composto não catabólico produzido por uma célula hospedeira
MX2018015766A (es) Un proceso para producir cuero.
EA200801329A1 (ru) Способ промышленного получения диалкилкарбоната и диола с высоким выходом
AR123935A1 (es) COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g